id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-266202-3qku90ml	Billington, John	Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks	2020-06-01		.txt	text/plain	4323	237	42	8 At the same time, national and regional government programs like the US Biomedical Advanced Research and Development Authority (BARDA) 9 and the European Union's Innovative Medicines Initiative (IMI) 10 have sustained their commitment to R&D for EID response. 17 Although 4 vaccines based on the new strain were approved by the US Food and Drug Administration (FDA) and shipped globally just 4 months after WHO had declared H1N1 a public health emergency of international concern (PHEIC), they came too late and in insufficient quantities to prevent the estimated 151,700 to 575,400 deaths that occurred worldwide in the first year of the pandemic. 24, 25 While responding to global infectious disease emergencies is central to the vaccine industry's public health mission, business leaders may not always act, and shareholders may not always approve the necessary investments, because the business risks of EID vaccine development tend to outweigh any return on investment.	./cache/cord-266202-3qku90ml.txt	./txt/cord-266202-3qku90ml.txt